---
schema_version: "secwatch.filing_event.v1"
accession: "0001662774-25-000031"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:21:12.511820+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026

## Summary
- 63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.
- Early enrollment conclusion by end of June would provide ~80% power for primary endpoint.
- Cash and investments $31.6M; net loss Q1 2025 of $15.0M ($0.34 per share).
- Topline results expected early 2026; NDA/MAA submissions planned H2 2026 if positive.
- All 19 study sites activated; slower enrollment cited due to challenging academic site environment.

## SEC filing metadata
- accession: 0001662774-25-000031
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/0001662774-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/qncx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662774-25-000031
- JSON: https://secwatch.observer/filing/0001662774-25-000031.json
- Plain text: https://secwatch.observer/filing/0001662774-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.